Intravenous iron therapy for patients with heart failure: expanding body of evidence.
作者信息
Adlbrecht Christopher
机构信息
Department of Cardiology, Vienna North Hospital - Clinic Floridsdorf and the Karl Landsteiner Institute for Cardiovascular and Critical Care Research Vienna, Austria.
出版信息
ESC Heart Fail. 2019 Aug;6(4):581-583. doi: 10.1002/ehf2.12490. Epub 2019 Jul 16.
Abstract
摘要
相似文献
1
Intravenous iron therapy for patients with heart failure: expanding body of evidence.心力衰竭患者的静脉铁剂治疗：证据不断增加
ESC Heart Fail. 2019 Aug;6(4):581-583. doi: 10.1002/ehf2.12490. Epub 2019 Jul 16.
2
Iron metabolism, iron deficiency, thrombocytosis, and the cardiorenal anemia syndrome.铁代谢、缺铁、血小板增多症及心肾贫血综合征
Oncologist. 2009;14 Suppl 1:22-33. doi: 10.1634/theoncologist.2009-S1-22.
3
Iron metabolism, anemia, and heart failure.铁代谢、贫血与心力衰竭。
J Am Coll Cardiol. 2011 Sep 13;58(12):1252-3. doi: 10.1016/j.jacc.2011.03.060.
4
Budget impact of intravenous ferric carboxymaltose in patients with chronic heart failure and iron deficiency in France.法国慢性心力衰竭伴缺铁患者静脉注射羧基麦芽糖铁的预算影响。
ESC Heart Fail. 2019 Jun;6(3):559-569. doi: 10.1002/ehf2.12432. Epub 2019 Apr 25.
5
Disordered iron homeostasis in chronic heart failure: prevalence, predictors, and relation to anemia, exercise capacity, and survival.慢性心力衰竭中铁代谢紊乱：患病率、预测因素以及与贫血、运动能力和生存的关系。
J Am Coll Cardiol. 2011 Sep 13;58(12):1241-51. doi: 10.1016/j.jacc.2011.04.040.
6
Retrospective analysis into differences in heart failure patients with and without iron deficiency or anaemia.回顾性分析伴或不伴缺铁或贫血的心力衰竭患者的差异。
ESC Heart Fail. 2019 Aug;6(4):840-855. doi: 10.1002/ehf2.12485. Epub 2019 Jul 9.
7
Structural and functional abnormalities in iron-depleted heart.缺铁性心脏的结构和功能异常。
Heart Fail Rev. 2019 Mar;24(2):269-277. doi: 10.1007/s10741-018-9738-4.
8
Anemia and iron deficiency in heart failure.心力衰竭中的贫血和缺铁
Rev Port Cardiol. 2014 Jan;33(1):39-44. doi: 10.1016/j.repc.2013.06.003. Epub 2013 Nov 9.
9
[Iron and stable ischemic heart disease - lessons from heart failure].[铁与稳定性缺血性心脏病——心力衰竭的教训]
G Ital Cardiol (Rome). 2019 Oct;20(10):559-573. doi: 10.1714/3228.32055.
10
Anemia in heart failure: marker or mediator of adverse prognosis?心力衰竭中的贫血：不良预后的标志物还是介导因素？
J Am Coll Cardiol. 2008 Feb 5;51(5):577-8. doi: 10.1016/j.jacc.2007.09.052.
引用本文的文献
1
Iron replacement therapy in heart failure: a literature review.心力衰竭中的铁替代疗法：文献综述
Egypt Heart J. 2021 Sep 26;73(1):85. doi: 10.1186/s43044-021-00211-3.
2
Primary care heart failure service identifies a missed cohort of heart failure patients with reduced ejection fraction.初级保健心力衰竭服务发现了一个射血分数降低的心力衰竭患者的遗漏队列。
Eur Heart J. 2022 Feb 3;43(5):405-412. doi: 10.1093/eurheartj/ehab629.
3
Anemia and iron deficiency in heart failure: extending evidences from chronic to acute setting.心力衰竭中的贫血与缺铁：从慢性情况到急性情况的证据扩展
Intern Emerg Med. 2021 Jan;16(1):167-170. doi: 10.1007/s11739-020-02434-9. Epub 2020 Jul 10.
本文引用的文献
1
Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.铁羧基麦芽糖对计算的血浆容量状态和临床充血的影响：一项 FAIR-HF 子研究。
ESC Heart Fail. 2019 Aug;6(4):621-628. doi: 10.1002/ehf2.12462. Epub 2019 May 30.
2
The use of diuretics in heart failure with congestion - a position statement from the Heart Failure Association of the European Society of Cardiology.心力衰竭伴充血时利尿剂的应用——欧洲心脏病学会心力衰竭协会立场声明。
Eur J Heart Fail. 2019 Feb;21(2):137-155. doi: 10.1002/ejhf.1369. Epub 2019 Jan 1.
3
Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.血管紧张素-脑啡肽酶抑制剂在急性失代偿性心力衰竭中的应用。
N Engl J Med. 2019 Feb 7;380(6):539-548. doi: 10.1056/NEJMoa1812851. Epub 2018 Nov 11.
4
Prediction of readmissions and mortality in patients with heart failure: lessons from the IMPEDANCE-HF extended trial.心力衰竭患者再入院和死亡的预测：来自 IMPEDANCE-HF 扩展试验的经验教训。
ESC Heart Fail. 2018 Oct;5(5):788-799. doi: 10.1002/ehf2.12330. Epub 2018 Aug 10.
5
Iron deficiency in chronic heart failure: case-based practical guidance.慢性心力衰竭中的缺铁：基于病例的实用指南。
ESC Heart Fail. 2018 Oct;5(5):764-771. doi: 10.1002/ehf2.12333. Epub 2018 Aug 2.
6
Comparative safety of intravenous ferumoxytol versus ferric carboxymaltose in iron deficiency anemia: A randomized trial.静脉注射铁羧麦芽糖与低分子右旋糖酐铁治疗缺铁性贫血的安全性比较：一项随机试验。
Am J Hematol. 2018 May;93(5):683-690. doi: 10.1002/ajh.25060. Epub 2018 Feb 24.
7
Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Chronic Heart Failure and Iron Deficiency.羧麦芽糖铁对慢性心力衰竭合并缺铁患者运动能力的影响
Circulation. 2017 Oct 10;136(15):1374-1383. doi: 10.1161/CIRCULATIONAHA.117.027497. Epub 2017 Jul 12.
8
Effect of Oral Iron Repletion on Exercise Capacity in Patients With Heart Failure With Reduced Ejection Fraction and Iron Deficiency: The IRONOUT HF Randomized Clinical Trial.口服补铁对射血分数降低的心力衰竭合并缺铁患者运动能力的影响：IRONOUT HF随机临床试验
JAMA. 2017 May 16;317(19):1958-1966. doi: 10.1001/jama.2017.5427.
9
Effects of intravenous iron therapy in iron-deficient patients with systolic heart failure: a meta-analysis of randomized controlled trials.静脉铁剂治疗缺铁性收缩性心力衰竭患者的效果：随机对照试验的荟萃分析。
Eur J Heart Fail. 2016 Jul;18(7):786-95. doi: 10.1002/ejhf.473. Epub 2016 Jan 28.
10
The impact of intravenous ferric carboxymaltose on renal function: an analysis of the FAIR-HF study.静脉注射羧麦芽糖铁对肾功能的影响：FAIR-HF研究分析
Eur J Heart Fail. 2015 Mar;17(3):329-39. doi: 10.1002/ejhf.229. Epub 2015 Feb 11.
Zotero 插件